Merck Sharp & Dohme Llc

This phase 3 study tested the 9-valent HPV vaccine (Gardasil 9) in over 1,000 Japanese males aged 16 to 26. The goal was to see if the vaccine could prevent persistent HPV infections that can lead to genital warts and anal cancers. Participants received either the vaccine or a pl…

This completed Phase 3 study tested a 9-valent HPV vaccine in nearly 2,000 healthy Chinese females aged 9 to 45. The goal was to see if the vaccine triggers a strong immune response and is safe. Participants received three doses, and researchers measured antibody levels over five…

This study tested a new vaccine called V116 in 882 children and teenagers aged 2 to 17 who have a higher risk of pneumococcal disease due to conditions like diabetes or chronic lung disease. The goal was to see if V116 is as good as or better than the current vaccine PPSV23 at tr…

This completed Phase 3 study tested a new vaccine called V116 in 518 adults aged 18 to 64 who are at increased risk for pneumococcal disease due to conditions like diabetes or chronic lung disease. The vaccine targets 21 strains of the bacteria that cause pneumonia and other infe…

This study looked at whether giving the HPV vaccine and the Moderna COVID-19 vaccine at the same time is safe and works well for children aged 9 to 11. About 165 boys and girls took part. The researchers compared kids who got both vaccines on the same day to those who got them on…

This study tested a new vaccine called V114 in over 7,000 healthy infants to see if it could prevent ear infections caused by certain pneumococcal bacteria. The vaccine was given alongside routine childhood shots. Researchers tracked how many babies got vaccine-type ear infection…

This early-stage study tested a new vaccine called V118 Formulation C in 65 healthy adults to see if it is safe and well-tolerated. Participants received either the new vaccine, an existing pneumonia vaccine (Prevnar 20), or a placebo. Researchers monitored for side effects like …

This study tested a new vaccine called V330 to see if it is safe and how well it triggers an immune response against norovirus, a virus that causes vomiting and diarrhea. The trial included 245 healthy adults aged 18-49 and 60-79. Participants received either the vaccine or a pla…

This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…

This clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…

This phase 3 trial tests whether a combination of enfortumab vedotin and pembrolizumab, given before and after bladder removal surgery, works better than standard chemotherapy for muscle-invasive bladder cancer. About 800 participants will be randomly assigned to one of the two t…

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if t…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help people with a specific type of advanced lung cancer live longer than standard chemotherapy. Over 1,200 participants with PD-L1 positive non-small cell lung cancer were randomly assi…

This study tests a new experimental drug, MK-4646, in people with HIV who have never taken HIV medications. The main goals are to see if the drug is safe and tolerable, and how much it can lower the amount of HIV in the blood. About 28 participants will receive the drug and be mo…

This study tested a drug called sotatercept (MK-7962) in 46 Japanese adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work harder. Participants took the drug alongside their usual treatments. The main goals were to see if it improve…

This study tested whether matching drug combinations to specific biomarkers in advanced non-small cell lung cancer could improve response. 245 patients who had not received prior treatment were grouped by two biomarkers (GEP and TMB) and given pembrolizumab plus another drug. The…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This study tested a new medication called efinopegdutide in 124 adults with fatty liver disease (also called MASLD). The goal was to see if taking the drug every two weeks or every week could safely reduce liver fat. After 28 weeks, the drug helped lower liver fat, and researcher…

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV-1 who had never taken HIV medication. The goal was to see if the new pill works as well as a standard three-drug regimen at keeping the virus under control. Results …

This phase 2 trial tested a drug called zilovertamab vedotin (MK-2140) in 140 people with diffuse large B-cell lymphoma that had returned or stopped responding to at least two prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The study …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 900 participants took part. The goal was to s…

This study tested whether adding other treatments to the drug pembrolizumab can help people with advanced melanoma that hasn't been treated before. Researchers checked safety and how many people's tumors shrank or disappeared. The trial involved 335 participants and was part of a…

This Phase 3 trial tested a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard treatments (regorafenib or TAS-102) in 441 people with advanced colorectal cancer that had stopped responding to prior therapy. The goal was to see if the new combin…

This early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…

This large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This phase 3 trial tested whether adding lenvatinib (Lenvima) to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with recurrent or metastatic head and neck squamous cell carcinoma. The study enrolled 511 participants whose tumors express PD-L1. Researche…

This phase 3 trial tested whether adding lenvatinib and pembrolizumab to standard chemotherapy helps people with advanced gastroesophageal cancer live longer. About 895 participants received either the new combination or chemo alone. The study is complete, and results will show i…

This early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to se…

This large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) can prevent liver cancer from coming back in people who had successful surgery or ablation. 959 participants received either pembrolizumab or a placebo every three weeks. The study measured ho…

This Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…

This phase 3 trial tested whether people with HIV whose virus is already suppressed can safely switch to a new two-drug pill (doravirine/islatravir) instead of staying on their current three-drug regimen (BIC/FTC/TAF). About 643 participants were randomly assigned to either switc…

This study tested a new drug called MK-0616 (enlicitide) to see if it lowers 'bad' LDL cholesterol better than current pills (ezetimibe, bempedoic acid, or both). About 300 adults with high cholesterol and heart disease risk took part. The main goal was to check cholesterol reduc…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…

This early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the…

This phase 3 trial tested the drug pembrolizumab (Keytruda) against a placebo in 1,177 people with early-stage non-small cell lung cancer who had already had surgery. The goal was to see if pembrolizumab could delay the cancer from coming back. Participants received either the dr…

This phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This Phase 3 trial tested whether adding lenvatinib to pembrolizumab (Keytruda) helps people with recurrent or metastatic head and neck squamous cell carcinoma that has a specific marker (PD-L1). The study enrolled 112 participants and compared the combination against pembrolizum…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent skin cancer from returning in people with high-risk locally advanced squamous cell carcinoma who had already undergone surgery and radiation. About 450 participants were randomly assigned…

This Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent kidney cancer from coming back after surgery. Nearly 1,000 participants who had their kidney removed due to renal cell carcinoma received either pembrolizumab or a placebo. The st…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…

This large Phase 3 trial tested adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy for people with advanced stomach cancer that cannot be removed by surgery. Over 1,500 participants received either pembrolizumab plus chemo or a placebo plus chemo. The…

This Phase 3 trial tested an oral drug called enlicitide decanoate (MK-0616) in 303 adults with heterozygous familial hypercholesterolemia, an inherited condition causing very high cholesterol. Participants took either the drug or a placebo daily for up to 52 weeks. The main goal…

This study tested whether adding the drug olaparib to standard treatment (pembrolizumab plus chemotherapy) helps people with advanced squamous non-small cell lung cancer live longer or keep the cancer from growing. About 850 adults who had not been treated before took part. The g…

This phase 3 trial tested whether adding the drug olaparib (Lynparza) to standard treatment with pembrolizumab (Keytruda) and chemotherapy helps people with advanced nonsquamous lung cancer live longer without their disease worsening. Over 1,000 participants received either olapa…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation helps people with high-risk, locally advanced cervical cancer live longer without their cancer growing. About 1,060 participants received either pembrolizumab or a placebo alongside t…

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…

This completed Phase 3 study tested whether switching to a once-daily combination pill (doravirine/islatravir) works as well as staying on standard HIV therapy. 672 adults with HIV whose virus was already suppressed took part. Results showed the new pill kept the virus under cont…

This phase 3 trial tested whether adding lenvatinib to pembrolizumab helps people with untreated advanced non-small cell lung cancer whose tumors have PD-L1 levels of 1% or higher. Over 600 participants received either the combination or pembrolizumab alone. The study measured ho…

This completed Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) works better than the targeted drug brentuximab vedotin (Adcetris) for people with classical Hodgkin lymphoma that has relapsed or not responded to prior therapy. 304 participants were ran…

This study tested an experimental drug called MK-2060 in 506 adults with end-stage kidney disease who need regular dialysis through a special tube (graft) in their arm. The goal was to see if the drug could prevent dangerous blood clots from blocking the graft, which would requir…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. About 674 adults with stage III or IV melanoma took part. The goal was to see if the combination helps people live lo…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…

This study tested a new antibiotic called MK-7655A in 115 children from birth to 18 years old who had serious bacterial infections. The goal was to see if the drug is safe and works better than standard treatments. Children were randomly assigned to receive either the new drug or…

This phase 3 trial tested a new immunotherapy combination (pembrolizumab plus vibostolimab) with chemotherapy against the standard pembrolizumab-plus-chemotherapy for people with advanced non-small cell lung cancer. The study enrolled 739 participants who had not received prior t…

This phase 3 trial tested whether adding the targeted therapy lenvatinib to a standard combination of immunotherapy (pembrolizumab) and chemotherapy could help people with a common type of advanced lung cancer live longer. The study enrolled 761 adults with metastatic nonsquamous…

This study tested whether adding lenvatinib to pembrolizumab (immunotherapy) helps people with advanced bladder cancer live longer or keep their cancer from growing. It included 505 people whose cancer had spread and who could not take the chemotherapy drug cisplatin. The trial w…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, against the usual treatments for people with advanced colorectal cancer that had spread and stopped responding to prior therapy. About 563 adults took part. The goal was to see if the new combo helped peo…

This study tested whether adding pembrolizumab (an immunotherapy) to lenvatinib (a targeted therapy) works better than lenvatinib alone for people with advanced liver cancer. About 794 adults took part. The combination did not significantly improve how long patients lived or dela…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation helps people with locally advanced head and neck cancer live longer without the disease getting worse. Over 800 participants received either pembrolizumab plu…

This phase 3 trial tested whether combining the immunotherapy drug pembrolizumab with the targeted drug axitinib works better than the standard drug sunitinib alone for people with advanced kidney cancer. Over 860 patients took part. The combination helped patients live longer an…

This phase 3 study tested whether combining the immunotherapy pembrolizumab with the targeted therapy lenvatinib works better than standard chemotherapy for women with advanced or recurrent endometrial cancer. Over 800 participants received either the drug combo or chemo. The goa…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps women with advanced cervical cancer live longer and keep the disease from growing. Over 600 women with persistent, recurrent, or metastatic cervical cancer took part. The …

This study tested a drug called vorinostat in 56 people with certain types of lymphoma (follicular, other indolent B-cell, or mantle cell) that had returned or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared (respon…

This study tested whether switching from a daily HIV pill (Biktarvy) to a once-weekly combination of two experimental drugs (islatravir and ulonivirine) is safe and tolerable. It involved 161 adults whose HIV was already well-controlled on daily therapy. The goal was to see if a …

This phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…

This study tested an experimental drug called efinopegdutide in 381 adults with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to see if the drug could help the liver heal (resolve NASH) without making scarring worse. Participants r…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. It involved 131 Chinese participants with stage III or IV melanoma that could not be removed by surgery. The goal …

This large phase 3 trial tested the drug vericiguat in over 6,000 adults with chronic heart failure and a weakened heart pump. Participants took a daily pill or a placebo to see if the drug could lower the chance of dying from heart problems or being hospitalized for heart failur…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other drugs in 90 people with advanced esophageal cancer that had already progressed after one prior treatment. The goal was to see if these combinations are safe and can shrink tumors …

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard trastuzumab plus chemotherapy could improve outcomes for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study enrolled 738 participants …

This study looked at two ways of giving the drug sotatercept to people with pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making it hard to breathe. Researchers compared a standard weight-based dose to a simpler weight-banded dose to see how …

This study tested a combination of two drugs, pembrolizumab and lenvatinib, against standard chemotherapy for women with advanced or recurrent endometrial cancer. The goal was to see if the combo could slow cancer growth or improve survival better than chemo. The trial enrolled 1…

This study tested whether a combination of two drugs, lenvatinib and pembrolizumab, could help people with head and neck cancer that has returned or spread and is no longer responding to standard treatments. About 408 participants were randomly assigned to receive the combination…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 160 people with a rare type of advanced kidney cancer (non-clear cell renal cell carcinoma) that had not been treated before. The goal was to see if the drugs could shrink tumors. The study found that …

This phase 3 trial tests a new drug combination, MK-4280A (favezelimab plus pembrolizumab), against standard treatments (regorafenib or TAS-102) in 94 Chinese adults with advanced, PD-L1 positive colorectal cancer that has worsened after prior therapy. The main goal is to see if …

This study tested a combination of the immunotherapy drug pembrolizumab with two investigational drugs (MK-4830 or MK-0482) in 102 people with advanced non-small cell lung cancer that had not been treated before and tested positive for a protein called PD-L1. The main goal was to…

This phase II trial tested the immunotherapy drug pembrolizumab (Keytruda) alone or with another agent in 296 people with high-risk non-muscle-invasive bladder cancer that did not respond to standard BCG therapy. Participants received the drug intravenously every three weeks. The…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This study tested a diabetes pill called ertugliflozin in 166 children and teenagers aged 10 to 17 with type 2 diabetes. Participants took either the drug or a placebo for 24 weeks, along with their usual diabetes medicines. The main goal was to see if ertugliflozin could safely …

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other experimental drugs in people with stage III melanoma that can be surgically removed. The goal was to see if these combinations are safe and more effective than current treatments …

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps people with triple negative breast cancer. Over 1,100 participants received either pembrolizumab or a placebo with chemo before surgery, then continued the study drug after surgery. The goal wa…

This study tested the drug pembrolizumab (Keytruda) given every 6 weeks to 66 adults whose Hodgkin lymphoma or primary mediastinal large B-cell lymphoma had come back or not responded to prior treatment. The main goal was to see how many patients had their tumors shrink or disapp…

This study tested a new drug (MK-1454) injected directly into tumors, combined with the immunotherapy pembrolizumab, for people with advanced head and neck cancer that had not been treated before. The goal was to see if the combination worked better than pembrolizumab alone. 18 a…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This completed phase 1/2 trial tested the safety and effectiveness of pembrolizumab (Keytruda) alone or combined with other drugs (quavonlimab or lenvatinib) in 56 people with melanoma that had spread to the brain. Participants had not received steroids recently and were neurolog…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This early-stage trial tested a new drug called vibostolimab, either alone or combined with other cancer drugs, in 474 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the dr…

This early-stage study tested a new drug called MK-4464, given alone or with another drug (pembrolizumab), in 64 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the safety of the drug and how the body processes it. Thi…

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or stopped responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received lenvatinib daily, and…

This phase 2 trial tested whether adding an experimental drug (MK-4830) to standard chemotherapy and pembrolizumab (Keytruda) could better shrink high-grade serous ovarian cancer before surgery. 160 participants with stage III or IV disease received either the standard regimen or…

This study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to best supportive care helps Asian patients with advanced liver cancer live longer. 453 patients who had already received one prior treatment were randomly assigned to get either pembrolizum…

This early-stage study tested the safety of the antibiotic combination ceftolozane/tazobactam in 41 children with hospital-acquired pneumonia. The drug was given intravenously, with doses adjusted by age. Researchers monitored side effects and how the drug moved through the body.…

This large Phase 3 trial tested an experimental oral drug called enlicitide decanoate (MK-0616) in nearly 3,000 adults with high cholesterol, including those with a genetic form. The goal was to see if the drug safely lowers 'bad' LDL cholesterol more than a placebo over 24 weeks…

This early study tested a single shot of an experimental drug called MK-2060 in 14 people with stage 4 chronic kidney disease. The main goal was to see if it was safe and how the body handles it. Only the first part of the study was completed; the later parts were not started for…

This Phase 3 trial tested whether adding the targeted drug lenvatinib to standard chemotherapy plus the immunotherapy pembrolizumab helps people with advanced nonsquamous non-small cell lung cancer live longer without their cancer growing. The study enrolled 201 adults in China w…

This study tested a new medicine called clesrovimab in over 1,000 infants and children at high risk for severe RSV disease. The goal was to see if it is safe and works as well as or better than the current standard treatment, palivizumab. Participants received either clesrovimab …

This study tested a new vaccine called V116 in adults aged 50 and older to see if it is safe and works better than the current vaccine (PPSV23) at preventing pneumococcal disease, which can cause pneumonia and other serious infections. About 1,500 healthy adults received either V…

This large study tested a new medicine called clesrovimab to prevent RSV, a serious lung infection, in healthy babies born early or full-term. Over 3,600 infants received either the medicine or a placebo. The goal was to see if the medicine could reduce the number of babies who g…

This study tested a new vaccine called V116 in 313 adults with HIV to see if it safely prevents pneumococcal disease (a serious infection that can cause pneumonia and meningitis). Participants received either V116, a placebo, or an existing vaccine. The trial is complete, and res…

This study tested whether a higher-than-normal dose of MK-8527, a once-monthly pill to prevent HIV infection, affects heart rhythm. It involved 42 healthy adults and compared the drug to a placebo and an active control. The goal was to ensure the drug is safe for the heart before…

This study tested an experimental oral drug called MK-8527, taken once a month, to see if it is safe and how it works in the body for HIV prevention. 352 HIV-negative adults at low risk for infection participated. The main goals were to check for side effects and measure drug lev…

This study tested a new pneumococcal vaccine (V116) given at the same time as the seasonal flu shot in 1,080 adults aged 50 and older. The goal was to see if giving both vaccines together is safe and produces a strong immune response. Results help determine whether combining thes…

This early-stage study tested a new medicine called MK-2828 in 46 adults with type 2 diabetes. The main goal was to see if the drug is safe and well-tolerated. Researchers also measured how the drug moves through the body and its effect on a marker of inflammation (hsCRP). This i…

This early-stage study tested the safety of a new drug called MK-8189 (elpipodect) in 29 people with Alzheimer's disease who also had symptoms like agitation, aggression, or psychosis. The main goal was to see if the drug was safe and tolerable. Researchers monitored side effects…

This early-stage study tested the safety of a drug called MK-8189 in 34 adults with stable bipolar I disorder. Researchers monitored side effects and how the drug moved through the body. The goal was to see if the drug is safe enough for further testing, not to measure how well i…

This study tested a new medicine called MK-8189 in 224 adults having an acute episode of schizophrenia. Participants received either MK-8189, a placebo (inactive pill), or an active control (risperidone) for 4 weeks. The main goal was to see if MK-8189 reduces schizophrenia sympt…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 63 people with schizophrenia, including both younger and older adults, as well as healthy older volunteers. The main goal was to check the drug's safety and how the body processes it, not to cure the disease.…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Researchers monitored side effects and how many people stop…

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo. Participants received different doses of the drug, an active compar…

This early-stage trial tested the safety and how the body handles a new drug called MK-1167 in 28 people with Alzheimer's who were already taking donepezil. The study was completed and focused on side effects and drug levels in the blood. It does not yet show whether MK-1167 help…

This study looked at how a common heart medication, diltiazem, changes the amount of nemtabrutinib in the blood of 26 healthy adults. Researchers measured drug levels over time and checked for side effects. The goal was to understand if diltiazem affects how the body processes ne…

This completed phase 1 study in 14 healthy men looked at how the experimental prostate cancer drug opevesostat behaves in the body when taken with or without another drug called itraconazole. The goal was to measure drug levels and safety, not to treat cancer. Results will help g…

This completed Phase 1 trial in 41 healthy adults tested whether multiple doses of MK-2828, a potential heart failure treatment, affect how the body processes rosuvastatin and furosemide. The goal was to check for drug interactions that could impact future dosing. The study provi…

This early-stage trial tested two different forms of MK-1167, an experimental drug aimed at treating Alzheimer's symptoms, in 16 healthy adults. Researchers measured how the drug moves through the body and checked for safety. The goal is to find a safe dose before testing it in p…

This study looks at how a new drug called ulonivirine changes the way the body processes two common medications: atorvastatin (for cholesterol) and metformin (for diabetes). Twelve healthy adults will take these drugs with and without ulonivirine to compare drug levels in the blo…

This study looked at how enlicitide, an experimental drug, enters the bloodstream when given in different tablet forms. Thirty healthy adults took part to help researchers understand the drug's behavior and check for any side effects. The goal was to compare the new tablet versio…

This completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured dru…

This study looked at how a single dose of an experimental drug called MK-1084 changes the way the body processes two common medicines: rosuvastatin (for cholesterol) and metformin (for diabetes). Sixteen healthy adults took part in this crossover study, where each person received…

This early-stage study tested a new drug called MK-8189 in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to see if the drug is safe and how it behaves in the body. Researchers measured drug levels and side effects, but this study did not …

This early-stage study tested a single 4 mg dose of the drug elpipodect (MK-8189) in 14 people—some with mild or moderate liver problems and some healthy. Researchers measured how much drug stayed in the blood and for how long. The goal was to see if liver impairment changes drug…

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) affects heart rhythm in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug causes a danger…

This early-stage trial tested the safety and tolerability of a new drug called MK-1167 in 30 healthy adults. Researchers monitored for side effects and how the body processes the drug. The study did not aim to treat any disease, but to gather essential safety data for future rese…

This study checked whether a new HIV medicine called MK-8507 (ulonivirine) causes any changes in heart rhythm. 62 healthy adults took either the study drug, a placebo, or a control drug to compare effects. The main goal was to see if the drug safely affects the heart's electrical…

This completed Phase 1 trial enrolled 16 healthy Chinese men to see how the body processes MK-4482 after single and multiple doses. Participants took 800 mg of MK-4482 by mouth, first as a single dose and then every 12 hours for several days. The study measured drug levels in the…

This completed Phase 1 study tested how the experimental HIV prevention drug MK-8527 moves into breast milk. Thirteen healthy lactating women took a single oral dose, then provided milk and blood samples over five days. The goal was to measure how much drug reaches the baby throu…

This completed Phase 1 study from Merck followed 6 healthy adults to see how the drug elpipodect (MK-8189) is absorbed, broken down, and eliminated. Participants took a single oral dose, and researchers measured the drug in blood, urine, and feces over time. The goal was purely t…

This study looked at how the experimental drug calderasib is absorbed, distributed, and removed from the body in 8 healthy adults. Participants took a single dose with a tiny radioactive tracer so researchers could measure the drug in blood, urine, and feces. The goal was to unde…

This completed Phase 1 study looked at how the drug MK-8527 moves through the body in people with mild or moderate liver impairment compared to healthy volunteers. Researchers measured drug levels in the blood over time to understand how liver function affects the drug. The study…

This completed Phase 1 study looked at how the drug bomedemstat behaves in people with mild or moderate liver impairment compared to healthy volunteers. Nine participants received a single dose, and researchers measured drug levels in the blood. The goal is to understand if liver…

This study looked at how the experimental prostate cancer drug opevesostat moves through the body in men with moderate liver impairment compared to healthy men. Sixteen male participants received a single dose, and researchers measured drug levels over time. The goal was to under…

This completed Phase 1 study enrolled 12 healthy lactating women to measure how much of the HIV drug MK-8591A (doravirine and islatravir) gets into breast milk. Participants took one oral tablet and provided breast milk and blood samples over 24 hours. The goal was to estimate th…

This completed Phase 1 study looked at how the drug MK-8527 is processed in people with moderate or severe kidney impairment compared to healthy volunteers. Eighteen participants received a single oral dose, and researchers measured drug levels in the blood over time. The goal wa…

This study looked at how the drug calderasib moves through the body when taken as two different tablet types and with or without food. 52 healthy adults took part to help researchers understand the drug's absorption and safety. The study does not aim to treat any disease.

This study looks at how the drug calderasib (MK-1084) behaves in people with moderate or severe kidney problems compared to healthy volunteers. Researchers will measure drug levels in the blood after a single dose to see if kidney function changes how the body processes it. The s…

This completed Phase 1 study tested how food, different pill forms, and a common heartburn drug (a proton pump inhibitor) change the levels of the experimental drug calderasib in the blood. Fifty-six healthy adults each took a single dose of calderasib under various conditions. T…

This completed Phase 1 study looked at how two common drugs—itraconazole (an antifungal) and phenytoin (a seizure medicine)—change the amount of calderasib in the blood of 28 healthy adults. Researchers measured calderasib levels over time after a single dose, alone and with each…

This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without cald…

This study looked at how a new HIV medicine (MK-4646) interacts with a tuberculosis drug (rifabutin) in 18 healthy adults. Researchers measured drug levels in the blood and checked for side effects when the two were taken together. The goal was to gather safety and dosing informa…

This completed Phase 1 study looked at how a radioactive form of the drug ulonivirine is absorbed, broken down, and removed from the body. Eight healthy adults took a single oral dose, and researchers measured the drug and its breakdown products in blood, urine, and stool. The go…

This completed Phase 1 study tested two forms of the drug sotatercept in 146 healthy women who cannot become pregnant. One form is a liquid in an autoinjector pen, the other is a powder that must be mixed before injection. The goal was simply to see how the body absorbs and proce…

This completed Phase 1 study gave a single IV dose of radiolabeled MK-5475 to 8 healthy men to see how the drug is absorbed, broken down, and removed from the body. Researchers measured levels in blood, urine, and feces over time. The study does not test treatment for any disease…

This completed Phase 1 study looked at how the drug MK-5684 behaves in the body of men with severe kidney disease or end-stage renal disease compared to healthy men. Twenty-four participants received a single dose, and researchers measured drug levels in the blood over time. The …

This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with …

This study looked at how belzutifan, a drug for certain cancers, changes the way the body handles metformin, a common diabetes medicine. Fourteen healthy adults took metformin alone and then with belzutifan, and researchers measured drug levels in their blood and urine. The goal …

This completed Phase 1 trial studied 60 healthy adults to see if drinking coffee or tea changes how the body processes the drug enlicitide. Participants took enlicitide with coffee, tea, or water, and researchers measured drug levels in the blood. The goal is to understand if the…